IBX 13.5% 3.2¢ imagion biosystems limited

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-39

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 790 Posts.
    lightbulb Created with Sketch. 163
    I liked this part: "We need revenue pure and simple".

    Indeed we could look at it as a marketing exercise, sequencing activities and attempting to generate revenue at the earliest opportunity.

    In which case the simple, discrete Gadolinium replacement would have been a priority as 'the' trial ground on YoY, leading to revenue and SP appreciation while waiting for the big developments. And resulting in getting the name out there, to pave the way for bigger things.

    Instead, it seems like the long pole in the tent was the main focus, and quicker wins were missed. Which has seen us go from ~20c to the current SP, as there was nothing generating revenue, and only a cloud of vagueness upon which to speculate.

    It is obviously a complex space. But doing an environment analysis, identifying opportunities and risks, should be part of Management101.

    GLTAH.
 
watchlist Created with Sketch. Add IBX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.